{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T04:53:05Z","timestamp":1794286385579,"version":"4.9.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.purol.2022.01.001","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T07:57:52Z","timestamp":1643875072000},"page":"165-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Recommandations des Comit\u00e9s de canc\u00e9rologie (CC-AFU) et d\u2019infectiologie (CI-AFU) de l\u2019Association fran\u00e7aise d\u2019urologie pour la prise en charge effets ind\u00e9sirables et complications du BCG"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5722-2075","authenticated-orcid":false,"given":"F.","family":"Audenet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roumigui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5526-077X","authenticated-orcid":false,"given":"Y.","family":"Allory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Andrejak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7768-8558","authenticated-orcid":false,"given":"B.","family":"Prad\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Traxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bruy\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Saint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4345-3598","authenticated-orcid":false,"given":"Y.","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12S","key":"10.1016\/j.purol.2022.01.001_bib0280","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S1166-7087(20)30751-X","article-title":"Recommandations fran\u00e7aises du Comit\u00e9 de canc\u00e9rologie de l\u2019AFU\u2013actualisation 2020\u20132022\u00a0: tumeurs de la vessie","volume":"30","author":"Roupr\u00eat","year":"2020","journal-title":"Prog Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.01.001_bib0285","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.01.001_bib0290","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1\u00a0and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.01.001_bib0295","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0090-4295(00)01117-1","article-title":"Tolerability of bacille Calmette-Gu\u00e9rin maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.purol.2022.01.001_bib0300","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance Bacillus Calmette-Guerin for Ta T1\u00a0bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.01.001_bib0305","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.01.001_bib0310","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.02.040","article-title":"Maintenance Therapy with 3-monthly Bacillus Calmette-Gu\u00e9rin for 3\u00a0Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013","volume":"68","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2015","journal-title":"Eur Urol"},{"issue":"17","key":"10.1016\/j.purol.2022.01.001_bib0315","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/MD.0000000000000119","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature","volume":"93","author":"P\u00e9rez-Jacoiste As\u00edn","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"16","key":"10.1016\/j.purol.2022.01.001_bib0320","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.purol.2012.04.019","volume":"22","author":"Neuzillet","year":"2012","journal-title":"Prog Urol"},{"issue":"19","key":"10.1016\/j.purol.2022.01.001_bib0325","doi-asserted-by":"crossref","first-page":"6868","DOI":"10.1002\/cam4.4219","article-title":"Prognostic significance of bladder neck involvement in non-muscle-invasive bladder cancer: a SEER database analysis with 19,919\u00a0patients","volume":"10","author":"Zhan","year":"2021","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.purol.2022.01.001_bib0330","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.01.001_bib0335","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1\u00a0papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1\u00a0year versus 3\u00a0years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.01.001_bib0340","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.01.001_bib0345","series-title":"Non-muscle-invasive Bladder Cancer EAU Guidelines [Internet]","author":"Babjuk","year":"2021"},{"issue":"3","key":"10.1016\/j.purol.2022.01.001_bib0350","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.01.001_bib0355","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bju.13474","volume":"118","author":"Oddens","year":"2016","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.purol.2022.01.001_bib0360","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000020170","article-title":"What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?","volume":"37","author":"Zlotta","year":"2000","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.01.001_bib0365","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0022-5347(01)65185-1","article-title":"Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85\u00a0complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer","volume":"157","author":"Zlotta","year":"1997","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.01.001_bib0370","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1158\/2326-6066.CIR-20-0638","article-title":"Therapy of established tumors with rationally designed multiple agents targeting diverse immune-tumor interactions: engage, expand, enable","volume":"9","author":"Fabian","year":"2021","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.purol.2022.01.001_bib0375","doi-asserted-by":"crossref","first-page":"e001691","DOI":"10.1136\/jitc-2020-001691","article-title":"Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve","volume":"9","author":"Fabian","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.purol.2022.01.001_bib0380","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<83::AID-IJC13>3.0.CO;2-R","article-title":"Role of a bacillus Calmette-Gu\u00e9rin fibronectin attachment protein in BCG-induced antitumor activity","volume":"86","author":"Zhao","year":"2000","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.purol.2022.01.001_bib0385","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1128\/iai.56.12.3046-3051.1988","article-title":"Characterization of fibronectin-binding antigens released by Mycobacterium tuberculosis and Mycobacterium bovis BCG","volume":"56","author":"Abou-Zeid","year":"1988","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.purol.2022.01.001_bib0390","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-5347(05)65469-9","article-title":"Prognostic value of a T helper 1\u00a0urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer","volume":"167","author":"Saint","year":"2002","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.01.001_bib0395","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1464-410X.1995.tb07309.x","article-title":"The persistence of bacille Calmette-Gu\u00e9rin in the bladder after intravesical treatment for bladder cancer","volume":"75","author":"Bowyer","year":"1995","journal-title":"Br J Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.01.001_bib0400","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0022-5347(05)66410-5","article-title":"The fate of bacillus Calmette-Guerin after intravesical instillation","volume":"165","author":"Durek","year":"2001","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.01.001_bib0405","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/S0022-5347(01)68169-2","article-title":"Detection of bacillus Calmette-Guerin in the blood by the polymerase chain reaction method of treated bladder cancer patients","volume":"158","author":"Tuncer","year":"1997","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.01.001_bib0410","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1464-410X.2009.08469.x","article-title":"Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Gu\u00e9rin-induced toxicity?","volume":"104","author":"Damiano","year":"2009","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.purol.2022.01.001_bib0415","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/iju.12609","article-title":"Efficacy and tolerance of one-third full dose bacillus Calmette-Gu\u00e9rin maintenance therapy every 3\u00a0months or 6\u00a0months: two-year results of URO-BCG-4\u00a0multicenter study","volume":"22","author":"Pfister","year":"2015","journal-title":"Int J Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.01.001_bib0420","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/CAD.0000000000000456","article-title":"Final results of the phase III URO-BCG 4\u00a0multicenter study: efficacy and tolerance of one-third dose BCG maintenance in nonmuscle invasive bladder cancer","volume":"28","author":"Nouhaud","year":"2017","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1016\/j.purol.2022.01.001_bib0425","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","article-title":"Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer","volume":"147","author":"Lamm","year":"1992","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.01.001_bib0430","first-page":"542","article-title":"[Intravesical BCG-therapy: comparison of side effects of Connaught (Toronto) and Pasteur (Paris) strains]","volume":"10","author":"Champetier","year":"2000","journal-title":"Prog Urol"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.purol.2022.01.001_bib0435","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000052380","article-title":"Modified induction course: a solution to side-effects?","volume":"37","author":"Bassi","year":"2000","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.01.001_bib0440","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.01.001_bib0445","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0022-5347(01)64936-X","article-title":"Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911","volume":"157","author":"Vegt","year":"1997","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.01.001_bib0450","first-page":"604","article-title":"[Surveillance of the safety of intravesical BCG therapy in France: quantitative analysis of serious adverse events notified over a period of five years]","volume":"12","author":"Debois","year":"2002","journal-title":"Prog Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.01.001_bib0455","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7863\/jum.2007.26.5.671","article-title":"Tuberculous epididymo-orchitis after intravesical BCG therapy for superficial bladder carcinoma: sonographic findings","volume":"26","author":"Salvador","year":"2007","journal-title":"J Ultrasound Med"},{"issue":"2","key":"10.1016\/j.purol.2022.01.001_bib0460","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.juro.2012.09.049","article-title":"Connaught and Russian strains showed the highest direct antitumor effects of different Bacillus Calmette-Gu\u00e9rin substrains","volume":"189","author":"Secanella-Fandos","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2022.01.001_bib0465","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.urology.2018.04.039","article-title":"Patient compliance with maintenance intravesical therapy for nonmuscle invasive bladder cancer","volume":"118","author":"Tapiero","year":"2018","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.purol.2022.01.001_bib0470","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","article-title":"The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1\u00a0bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"Sylvester","year":"2003","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.01.001_bib0475","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2014A current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.01.001_bib0480","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00296-005-0059-2","article-title":"Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review","volume":"26","author":"Tinazzi","year":"2006","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1016\/j.purol.2022.01.001_bib0485","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/00042737-200410000-00012","article-title":"Bacillus Calmette-Gu\u00e9rin-induced granulomatous hepatitis in a patient with a superficial bladder carcinoma","volume":"16","author":"Van Outryve","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.purol.2022.01.001_bib0490","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.autrev.2010.11.009","article-title":"The kaleidoscope of glucorticoid effects on immune system","volume":"10","author":"Zen","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"7\u20138","key":"10.1016\/j.purol.2022.01.001_bib0495","first-page":"E540","article-title":"Complications of intravesical bacillus calmette-gu\u00e9rin","volume":"8","author":"Macleod","year":"2014","journal-title":"Can Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.01.001_bib0500","first-page":"5671","article-title":"Isoniazid resistance among Bacillus Calmette Guerin strains: implications on bladder cancer immunotherapy related infections","volume":"18","author":"Malhotra","year":"2011","journal-title":"Can J Urol"},{"key":"10.1016\/j.purol.2022.01.001_bib0505","doi-asserted-by":"crossref","first-page":"6230409","DOI":"10.1155\/2019\/6230409","article-title":"Clinical spectrum of complications induced by intravesical immunotherapy of Bacillus Calmette-Gu\u00e9rin for bladder cancer","volume":"2019","author":"Liu","year":"2019","journal-title":"J Oncol"},{"issue":"5","key":"10.1016\/j.purol.2022.01.001_bib0510","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1\u00a0and Carcinoma In Situ)\u20132019\u00a0Update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.01.001_bib0515","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.01.001_bib0520","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.juro.2012.10.070","article-title":"Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Gu\u00e9rin treatment","volume":"189","author":"Johnson","year":"2013","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.01.001_bib0525","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.urolonc.2020.11.037","article-title":"BCG infection (BCGitis) following intravesical instillation for bladder cancer and time interval between treatment and presentation: a systematic review","volume":"39","author":"Cabas","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.purol.2022.01.001_bib0530","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2466-14-35","article-title":"BCG-induced pneumonitis with lymphocytic pleurisy in the absence of elevated KL-6","volume":"14","author":"Tobiume","year":"2014","journal-title":"BMC Pulm Med"},{"issue":"12","key":"10.1016\/j.purol.2022.01.001_bib0535","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.autrev.2013.06.017","article-title":"Reactive arthritis induced by intravesical BCG therapy for bladder cancer: our clinical experience and systematic review of the literature","volume":"12","author":"Bernini","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.purol.2022.01.001_bib0540","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.urology.2004.07.027","article-title":"Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Gu\u00e9rin therapy for superficial bladder carcinoma","volume":"65","author":"Falkensammer","year":"2005","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.purol.2022.01.001_bib0545","first-page":"1554","article-title":"Investigation of granulomatous prostatitis incidence following intravesical BCG therapy","volume":"7","author":"Balasar","year":"2014","journal-title":"Int J Clin Exp Med"},{"issue":"5","key":"10.1016\/j.purol.2022.01.001_bib0275","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0022-5347(05)67025-5","article-title":"Elevated prostate specific antigen serum levels after intravesical instillation of bacillus Calmette-Guerin","volume":"164","author":"Leibovici","year":"2000","journal-title":"J Urol"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S116670872200001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S116670872200001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:35:21Z","timestamp":1761114921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S116670872200001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S116670872200001X"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2022.01.001","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommandations des Comit\u00e9s de canc\u00e9rologie (CC-AFU) et d\u2019infectiologie (CI-AFU) de l\u2019Association fran\u00e7aise d\u2019urologie pour la prise en charge effets ind\u00e9sirables et complications du BCG","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2022.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}